NCT04622111View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

May 5, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

CPL207280

IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

DRUG

Placebo

matching placebo tablet

DRUG

Metformin hydrochloride 750 mg

IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).

Trial Locations (1)

05-830

BioResearch Group Sp. z o.o., Kajetany

Sponsors

Lead Sponsor

Celon Pharma SA
All Listed Sponsors
collaborator

National Center for Research and Development, Poland

OTHER

lead

Celon Pharma SA

INDUSTRY